Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARALAST NP in A1PI Deficiency with COPD-E
NCT04440488Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Planned start Mar 2021; status: withdrawn.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04440488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440488.